{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:54:07Z","timestamp":1760100847841},"reference-count":27,"publisher":"Oncology Nursing Society (ONS)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ONF"],"published-print":{"date-parts":[[2016,1,1]]},"DOI":"10.1188\/16.onf.114-117","type":"journal-article","created":{"date-parts":[[2016,1,25]],"date-time":"2016-01-25T16:29:24Z","timestamp":1453739364000},"page":"114-117","source":"Crossref","is-referenced-by-count":2,"title":["Management of Individuals With a Mutation in the Ataxia Telangiectasia Mutated Gene"],"prefix":"10.1188","volume":"43","author":[{"given":"Suzanne","family":"Mahon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2016,1,1]]},"reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Ahmed, M., & Rahman, N. (2006). ATM and breast cancer susceptibility. Oncogene, 25, 5906\u20135911. doi:10.1038\/sj.onc.1209873","DOI":"10.1038\/sj.onc.1209873"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Aloraifi, F., McDevitt, T., Martiniano, R., McGreevy, J., McLaughlin, R., Egan, C.M., . . . Bracken, A.P. (2015). Detection of novel germline mutations for breast cancer in non-BRCA1\/2 families. FEBS Journal, 282, 3424\u20133437. doi:10.1111\/febs.13352","DOI":"10.1111\/febs.13352"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Beltran, H., Yelensky, R., Frampton, G.M., Park, K., Downing, S.R., MacDonald, T.Y.,. . . Rubin, M.A. (2013). Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. European Urology, 63, 920\u2013926. doi:10.1016\/j.eururo.2012.08.053","DOI":"10.1016\/j.eururo.2012.08.053"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Bernstein, J.L., Haile, R.W., Stovall, M., Boice, J.D., Jr., Shore, R.E., Langholz, B., . . . Concannon, P. (2010). Radiation exposure, the ATM gene, and contralateral breast cancer in the women\u2019s environmental cancer and radiation epidemiology study. Journal of the National Cancer Institute, 102, 475\u2013483. doi:10.1093\/jnci\/djq055","DOI":"10.1093\/jnci\/djq055"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Chessa, L., Piane, M., Magliozzi, M., Torrente, I., Savio, C., Lulli, P., . . . Dallapiccola, B. (2009). Founder effects for ATM gene mutations in Italian ataxia telangiectasia families. Annals of Human Genetics, 73, 532\u2013539. doi:10.1111\/j.1469-1809.2009.00535.x","DOI":"10.1111\/j.1469-1809.2009.00535.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Economopoulou, P., Dimitriadis, G., & Psyrri, A. (2015). Beyond BRCA: New hereditary breast cancer susceptibility genes. Cancer Treatment Reviews, 41, 1\u20138. doi:10.1016\/j.ctrv.2014.10.008","DOI":"10.1016\/j.ctrv.2014.10.008"},{"key":"7","unstructured":"Gatti, R. (2010). Ataxia-telangectasia. In R.A. Pagon, M.P. Adam, H.H. Ardinger, S.E. Wallace, A. Amemiya, L.J.H. Bean, . . . K. Stephens (Eds.), GeneReviews\u00ae. Seattle, WA: University of Washington, Seattle. Retrieved from http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK26468\/?report=reader"},{"key":"8","unstructured":"Genetics Home Reference. (2015). ATM. Retrieved from http:\/\/ghr.nlm.nih.gov\/gene\/ATM"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Gilardini Montani, M.S., Prodosmo, A., Stagni, V., Merli, D., Monteonofrio, L., Gatti, V., . . . Soddu, S. (2013). ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition. Journal of Experimental and Clinical Cancer Research, 32, 95. doi:10.1186\/1756-9966-32-95","DOI":"10.1186\/1756-9966-32-95"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Gra\u00f1a, B., Fachal, L., Darder, E., Balma\u00f1a, J., Ram\u00f3n Y Cajal, T., Blanco, I., . . . Brunet, J. (2011). Germline ATM mutational analysis in BRCA1\/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry. Breast Cancer Research and Treatment, 128, 573\u2013579. doi:10.1007\/s10549-011-1462-x","DOI":"10.1007\/s10549-011-1462-x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Hammond, E.M., & Muschel, R.J. (2014). Radiation and ATM inhibition: The heart of the matter. Journal of Clinical Investigation, 124, 3289\u20133291. doi:10.1172\/JCI77195","DOI":"10.1172\/JCI77195"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Kanagal-Shamanna, R., Portier, B.P., Singh, R.R., Routbort, M.J., Aldape, K.D., Handal, B.A., . . . Patel, K.P. (2014). Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: Promises and challenges for routine clinical diagnostics. Modern Pathology, 27, 314\u2013327. doi:10.1038\/modpathol.2013.122","DOI":"10.1038\/modpathol.2013.122"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Kapoor, N.S., Curcio, L.D., Blakemore, C.A., Bremner, A.K., McFarland, R.E., West, J.G., & Banks, K.C. (2015). Multigene panel testing detects equal rates of pathogenic BRCA1\/2 mutations and has a higher diagnostic yield compared to limited BRCA1\/2 analysis alone in patients at risk for hereditary breast cancer. Annals of Surgical Oncology, 22, 3282\u20133288. doi:10.1245\/s10434-015-4754-2","DOI":"10.1245\/s10434-015-4754-2"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Kim, H.S., Choi, S.I., Min, H.L., Kim, M.A., & Kim, W.H. (2013). Mutation at intronic repeats of the ataxia-telangiectasia mutated (ATM) gene and ATM protein loss in primary gastric cancer with microsatellite instability. PLOS ONE, 8, e82769. doi:10.1371\/journal.pone.0082769","DOI":"10.1371\/journal.pone.0082769"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Lindor, N.M., McMaster, M.L., Lindor, C.J., & Greene, M.H. (2008). Concise handbook of familial cancer susceptibility syndromes\u2014Second edition. Journal of the National Cancer Institute. Monographs, 2008, 1\u201393. doi:10.1093\/jncimonographs\/lgn001","DOI":"10.1093\/jncimonographs\/lgn001"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Mahon, S.M. (2015). Management of patients with a genetic variant of unknown significance. Oncology Nursing Forum, 42, 316\u2013318. doi:10.1188\/15.ONF.316-318","DOI":"10.1188\/15.ONF.316-318"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Mitui, M., Nahas, S.A., Du, L.T., Yang, Z., Lai, C.H., Nakamura, K., . . . Gatti, R.A. (2009). Functional and computational assessment of missense variants in the ataxia-telangiectasia mutated (ATM) gene: Mutations with increased cancer risk. Human Mutation, 30, 12\u201321. doi:10.1002\/humu.20805","DOI":"10.1002\/humu.20805"},{"key":"18","unstructured":"National Comprehensive Cancer Network. (2015). NCCN Clinical Practice Guidelines in Oncology: Genetic\/familial high-risk assessment: Breast and ovarian [v.2.2015]. Retrieved from http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Ouillette, P., Li, J., Shaknovich, R., Li, Y., Melnick, A., Shedden, K., & Malek, S.N. (2012). Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia. Genes, Chromosomes and Cancer, 51, 1125\u20131132. doi:10.1002\/gcc.21997","DOI":"10.1002\/gcc.21997"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Pennington, K.P., Walsh, T., Harrell, M.I., Lee, M.K., Pennil, C.C., Rendi, M.H., . . . Swisher, E.M. (2014). Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clinical Cancer Research, 20, 764\u2013775. doi:10.1158\/1078-0432.CCR-13-2287","DOI":"10.1158\/1078-0432.CCR-13-2287"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Roberts, N.J., Jiao, Y., Yu, J., Kopelovich, L., Petersen, G.M., Bondy, M.L., . . . Klein, A.P. (2012). ATM mutations in patients with hereditary pancreatic cancer. Cancer Discovery, 2, 41\u201346. doi:10.1158\/2159-8290.CD-11-0194","DOI":"10.1158\/2159-8290.CD-11-0194"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Shiloh, Y. (2014). ATM: Expanding roles as a chief guardian of genome stability. Experimental Cell Research, 329, 154\u2013161. doi:10.1016\/j.yexcr.2014.09.002","DOI":"10.1016\/j.yexcr.2014.09.002"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Skowronska, A., Austen, B., Powell, J.E., Weston, V., Oscier, D.G., Dyer, M.J.,. . . Stankovic, T. (2012). ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele. Haematologica, 97, 142\u2013146. doi:10.3324\/haematol.2011.048827","DOI":"10.3324\/haematol.2011.048827"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Stagni, V., Oropallo, V., Fianco, G., Antonelli, M., Cin\u00e0, I., & Baril\u00e0, D. (2014). Tug of war between survival and death: Exploring ATM function in cancer. International Journal of Molecular Sciences, 15, 5388\u20135409. doi:10.3390\/ijms15045388","DOI":"10.3390\/ijms15045388"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Tavtigian, S.V., Oefner, P.J., Babikyan, D., Hartmann, A., Healey, S., Le Calvez-Kelm, F., . . . Chenevix-Trench, G. (2009). Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. American Journal of Human Genetics, 85, 427\u2013446. doi:10.1016\/j.ajhg.2009.08.018","DOI":"10.1016\/j.ajhg.2009.08.018"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Thompson, D., Duedal, S., Kirner, J., McGuffog, L., Last, J., Reiman, A., . . . Easton, D.F. (2005). Cancer risks and mortality in heterozygous ATM mutation carriers. Journal of the National Cancer Institute, 97, 813\u2013822. doi:10.1093\/jnci\/dji141","DOI":"10.1093\/jnci\/dji141"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Weber, A.M., & Ryan, A.J. (2015). ATM and ATR as therapeutic targets in cancer. Pharmacology and Therapeutics, 149, 124\u2013138. doi:10.1016\/j.pharmthera.2014.12.001","DOI":"10.1016\/j.pharmthera.2014.12.001"}],"container-title":["Oncology Nursing Forum"],"original-title":[],"link":[{"URL":"http:\/\/onf.ons.org\/onf\/43\/1\/management-individuals-mutation-ataxia-telangiectasia-mutated-gene","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T00:19:28Z","timestamp":1567556368000},"score":1,"resource":{"primary":{"URL":"http:\/\/onf.ons.org\/onf\/43\/1\/management-individuals-mutation-ataxia-telangiectasia-mutated-gene"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1,1]]}},"URL":"https:\/\/doi.org\/10.1188\/16.onf.114-117","relation":{},"ISSN":["0190-535X","1538-0688"],"issn-type":[{"value":"0190-535X","type":"print"},{"value":"1538-0688","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,1]]}}}